$1.47 Billion is the total value of Paradigm Biocapital Advisors LP's 31 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Sell | INCYTE CORP | $52,714,952 | -38.7% | 912,497 | -34.0% | 3.58% | -46.2% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $34,703,918 | -31.6% | 2,390,077 | -1.4% | 2.36% | -39.9% |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $27,728,957 | +11.3% | 2,421,743 | -0.1% | 1.88% | -2.2% |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -1,950,327 | -100.0% | -1.41% | – | |
| Exit | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $0 | – | -369,615 | -100.0% | -1.46% | – | |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -1.52% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -1,014,239 | -100.0% | -1.92% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -216,093 | -100.0% | -2.98% | – |
| ARGX | Exit | ARGENX SEput | $0 | – | -150,000 | -100.0% | -4.52% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -283,605 | -100.0% | -4.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-02 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.